Randomized controlled study of chemoimmunotherapy with bestatin of <font color="blue">acute_1</font> <font color="blue">nonlymphocytic_1</font> <font color="blue">leukemia_1</font> in adults . 
<br>
<br> A new immunomodulating agent , bestatin ( INN : Ubenimex has <font color="blue">low_2</font> <font color="blue">toxicity_2</font> <font color="blue">even_1</font> <font color="blue">after_1</font> <font color="blue">long_1</font> <font color="blue">-_1</font> <font color="blue">term_1</font> <font color="blue">oral_1</font> <font color="blue">administration_1</font> <font color="blue">and_1</font> <font color="blue">has_1</font> <font color="blue">significant_1</font> <font color="blue">modifications_1</font> <font color="blue">in_1</font> <font color="blue">immunological_3</font> <font color="blue">response_3</font> <font color="blue">._3</font> A cooperative randomized controlled study of bestatin immunotherapy in combination with remission maintenance chemotherapy for <font color="blue">adult_1</font> <font color="blue">acute_1</font> <font color="blue">nonlymphocytic_1</font> <font color="blue">leukemia_1</font> <font color="blue">(_1</font> <font color="blue">ANLL_1</font> <font color="blue">)_1</font> was performed . After induction of <font color="blue">complete_1</font> <font color="blue">remission_1</font> <font color="blue">,_1</font> patients were randomized to the bestatin group ( 30 mg / bw per os ( po ) daily ) and the control group . The 101 eligible cases ( bestatin : 48 , control : 53 ) were analyzed ; the bestatin group achieved <font color="blue">longer_1</font> <font color="blue">remission_3</font> than the control group and a statistically <font color="blue">significant_1</font> <font color="blue">longer_2</font> <font color="blue">survival_4</font> <font color="blue">._4</font> Though this <font color="blue">prolongation_2</font> <font color="blue">of_2</font> <font color="blue">remission_3</font> was not significant in the bestatin group compared to the control group in the 15 - 49 yr age group , in the 50 - 65 yr age group it was significantly longer . Bestatin is shown to be a clinically useful drug for immunotherapy of adult ANLL , since it has <font color="blue">prolonged_1</font> <font color="blue">survival_4</font> <font color="blue">and_2</font> <font color="blue">remission_3</font> especially in elderly patients , with <font color="blue">few_1</font> <font color="blue">side_1</font> <font color="blue">-_1</font> <font color="blue">effects_1</font> <font color="blue">._1</font>